**EBM Consult Focused Topic**

**Copyright EBM Consult, LLC.**

NOTE:

*Dear Author,*

*Please fill each section and row of every table where applicable. If no data exist, please designate that none exists or leave blank.*

*For a sample EBM Article to serve as an example or model go to*: <https://www.ebmconsult.com/articles/hints-head-impulse-exam-diagnosis-central-causes-dizziness>

**ARTICLE TITLE:**

Fill is your PICOTS: P stands for patient, I stands for intervention or treatment, C stands for comparison, O stands for outcome, T stands for the time frame for assessing the outcome…and S stands for the setting of the questions being asked.

**P =**

**I =**

**C =**

**O =**

**T =**

**S =**

***Take Home Point(s)*:**

* Take home point #1
* Take home point #2
* Take home point #3
* Take home point #4

***Summary:***

[Note: This where the concise summary or answer or explanation should go. This should be < ½ a page. It is also the place to make the evidence come alive and clinically relevant /useful to people. Feel free to add clinical pearls or things that are practical to working clinicians. This area is *NOT* meant to be an exhaustive summary of every study. It can summarize the totality of the data below in tables but not a study-by-study breakdown – no one wants to read all of that].

**Author(s):**  **Editor(s):**

**Reviewers:** *Note: you must have 1 peer reviewer review before submitting along with that reviewer’s name and contact info*

**Date Last Reviewed:** X

|  |
| --- |
| **Supporting Guideline Statements:** |
| **Organization Name & Date:**  “Insert rec here.”  **Guideline Rating:**  X  **Reference:**  [EXAMPLE FORMAT: Lip GY et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35(45):3155-79. PMID: 25154388] |
| **Organization Name & Date:**  “Insert rec here.”  **Guideline Rating:**  X  **Reference:**  Author etc …. PMID: #### |
| **Organization Name & Date:**  “Insert rec here.”  **Guideline Rating:**  X  **Reference:**  Author etc …. PMID: #### |
| **Organization Name & Date:**  “Insert rec here.”  **Guideline Rating:**  X  **Reference:**  Author etc …. PMID: #### |
|  |
| **Organization Name & Date:**  “Insert rec here.”  **Guideline Rating:**  X  **Reference:**  Author etc …. PMID: #### |

*Note: Provide the direct quotation of their statement here; also include class or level of evidence if provided and citation and PMID#*

Notes: ***DO NOT use bullets or insert tables within any of the rows or columns – ONLY single line text***. If a row is not applicable or info is not available from paper then leave it blank or empty.

|  |  |
| --- | --- |
| **META-ANALYSIS or COCHRANE REVIEWS:** | |
| **Reference:** [Insert here] | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria:** |  |
| **Exclusion Criteria:** |  |
| **Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| \*Add more here if needed |  |

|  |  |
| --- | --- |
| **ORIGINAL & SUPPORTING CLINICAL TRIALS (RCTs or other Prospective Studies)** | |
| **Reference:** [Insert here] | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria:** |  |
| **Exclusion Criteria:** |  |
| **Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| \*Add more here if needed |  |

|  |  |
| --- | --- |
| **COHORT STUDIES, CASE SERIES or CASE REPORTS:** | |
| **Reference:** [Insert here] | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria:** |  |
| **Exclusion Criteria:** |  |
| **Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| **Reference:** AUTHOR etc… <u>[link]http://www.ncbi.nlm.nih.gov/pubmed/?term=21621092|PubMed[/link]</u> | |
| **Level of Evidence:** | <http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf> |
| **PICOTS** | Insert PICOTS for this paper only |
| **Study Design:** |  |
| **Sample Size:** |  |
| **Population:** |  |
| **Inclusion Criteria** |  |
| **Exclusion Criteria** |  |
| **Groups & Interventions:** |  |
| **Other Treatments:** |  |
| **Follow-up or Duration:** |  |
| **Primary Endpoint (Purpose):** |  |
| **Secondary Endpoint(s):** |  |
| **Results:** |  |
| **Prevalence:** |  |
| **NNT/NNH:** |  |
| **Conclusions:** |  |
| **Location(s):** |  |
| **Funding:** |  |
| **ClinicalTrials.gov** |  |
| **Comment(s):** |  |
|  |  |
| \*Add more here if needed |  |

|  |
| --- |
| **Related Article & Reviews:** |
| **Reference:** see sample for format; include PMID |
| **Reference:** see sample for format; include PMID |

**Expert Comments:**

Note: you can put something here but the editorial staff will decide if it is used in final document

**Author(s):**

First and Last Name +

Title or Position +

Institution or Practice Site

Department

City, State

**Reviewer(s) That Reviewed PRIOR to Submission:**

First and Last Name +

Title or Position +

Institution or Practice Site

Department

City, State

NOTE:

Dear Author,

By submitting this article via email to EBM Consult or one of its editors you are releasing all rights and ownership of the contents to EBM Consult, LLC to use at its discretion including, but not limited too, printing, posting on the website. If you have any questions please feel free to email: [editor@ebmconsult.com](mailto:editor@ebmconsult.com)

Thank you.